Premium
MicroRNA‐222‐3p participates in the development of oral squamous cell carcinoma by targeting CDKN1B
Author(s) -
Yang Kaicheng,
Chen Yanping,
Cui Zifeng,
Chen He,
Yang Lei,
Zhao Jianguang,
Luo Fengyu,
Man Shasha,
Zhao Jianghui,
Jin Lingyu
Publication year - 2020
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/jop.12986
Subject(s) - microrna , basal cell , cancer research , medicine , carcinoma , oncology , pathology , biology , gene , genetics
Objective The aim of this study was to explore the potential role and regulatory mechanism of microRNA (miR)‐222‐3p in oral squamous cell carcinoma (OSCC). Methods The expression level and prognostic significance of miR‐222‐3p was detected in OSCC tissues. CCK‐8, transwell, and flow cytometry assays were used to explore the effect of miR‐222‐3p on cell proliferation, migration, invasion, and apoptosis. The influence of miR‐222‐3p on cyclin‐dependent kinase inhibitor 1B (CDKN1B) expression was evaluated by luciferase assays, real‐time polymerase chain reaction, and Western blot. Results We found that miR‐222‐3p was overexpressed in OSCC tissues, comparing with normal tissues. Kaplan‐Meier curves showed that OSCC patients with high expression of miR‐222‐3p ( P = .003) showed worse overall survival than those patients with low expression of miR‐222‐3p. Multivariate analysis showed that miR‐222‐3p ( P = .037) expression was an independent prognostic factor of OSCC patients. miR‐222‐3p promoted cell proliferation, migration and invasion and induced the apoptosis of SCC‐15 and Tca‐83 cells. Furthermore, luciferase reporter assays indicated that CDKN1B is targeted by miR‐222‐3p in OSCC cells. Overexpression of CDKN1B inhibited OSCC cell proliferation, migration, and invasion and promoted cell apoptosis rate. Conclusions miR‐222‐3p affects OSCC cell proliferation, migration, invasion, and apoptosis through targeting CDKN1B, and may be a potential prognostic biomarker for OSCC patients.